Ultragenyx Pharmaceutical Inc. lost $5.83 per diluted share in fiscal year 2025. This represents an increase of 7.3% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $5.83 per diluted share. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Ultragenyx Pharmaceutical Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$5.83
YoY+7.3%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
RARE EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Ultragenyx Pharmaceutical Inc.'s diluted earnings per share in fiscal year 2025?
Ultragenyx Pharmaceutical Inc. lost $5.83 per diluted share in fiscal year 2025.
How fast is Ultragenyx Pharmaceutical Inc.'s diluted earnings per share growing?
Ultragenyx Pharmaceutical Inc. (RARE) diluted earnings per share rose by 7.3% year over year, from -$6.29 to -$5.83 in fiscal year 2025.
What is Ultragenyx Pharmaceutical Inc.'s diluted earnings per share over the last twelve months?
Ultragenyx Pharmaceutical Inc. (RARE) reported a loss of $5.83 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Ultragenyx Pharmaceutical Inc.'s diluted earnings per share in the most recent quarter?
Ultragenyx Pharmaceutical Inc. (RARE) reported -$0.90 in diluted earnings per share in Q2 2026. This represents an increase of 23.1% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Ultragenyx Pharmaceutical Inc. (RARE) reported on that line in every period on record.
